Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kane Biotech Inc KNBIF


Primary Symbol: V.KNE

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired... see more

Recent & Breaking News (TSXV:KNE)

Kane Biotech to Present its revyve(TM) Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium

GlobeNewswire January 25, 2024

Kane Biotech Announces Special Meeting of Shareholders

GlobeNewswire January 18, 2024

Kane Biotech Announces Correction to Press Release

GlobeNewswire December 29, 2023

Kane Biotech Announces Amendment to its Credit Facility

GlobeNewswire December 28, 2023

Kane Biotech receives offer for STEM Animal Health subsidiary

Jocelyn Aspa December 20, 2023

Kane Biotech Receives Offer for its Interest in STEM Animal Health

GlobeNewswire December 20, 2023

Kane Biotech Announces Improved Third Quarter 2023 Financial Results

GlobeNewswire November 28, 2023

Kane Biotech to Release Third Quarter 2023 Financial Results on November 28, 2023 - Conference Call to Follow

GlobeNewswire November 21, 2023

Kane Biotech Strengthens Board with Biotech Executive

GlobeNewswire November 16, 2023

Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve(TM) Antimicrobial Wound Gel at Advanced Wound Care Fall Forum

GlobeNewswire November 2, 2023

Kane Biotech to Exhibit at Symposium on Advanced Wound Care Fall Forum

GlobeNewswire October 25, 2023

Kane Biotech Announces Closing of Fully Subscribed Private Placement Offering and Amendments to its Credit Facility

GlobeNewswire September 12, 2023

Kane Biotech Announces Second Quarter 2023 Financial Results

GlobeNewswire August 29, 2023

Kane Biotech to Release Second Quarter 2023 Financial Results on Aug 29, 2023 - Conference Call to Follow

GlobeNewswire August 22, 2023

Kane Biotech Announces Private Placement Offering and Proposed Amendments to its Credit Facility

GlobeNewswire August 3, 2023

Kane Biotech Engages Research Capital to Conduct Strategic Review of STEM Animal Health

GlobeNewswire August 2, 2023

Kane Biotech Announces Issuance of Restricted Share Units

GlobeNewswire June 23, 2023

Kane Biotech Announces First Quarter 2023 Financial Results

GlobeNewswire May 25, 2023

Kane Biotech attains FDA clearance for its coactiv+ wound gel

Brieanna McCutcheon  May 25, 2023

IIROC Trading Resumption - KNE

Canada NewsWire May 25, 2023